Ligand is a leading royalty aggregator that partners with biopharmaceutical companies to finance and advance late-stage development programs. We fund the clinical development and commercialization of high-value programs that can improve and extend lives around the world.
Our diversified portfolio of royalty assets generates consistent and predictable revenue streams for our shareholders. It includes treatments for cancer, kidney disease, diabetes, and other rare conditions that threaten lifespan and quality of life for billions of people. We also maintain and license our Captisol® and NITRICIL™ technology platforms with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world.
The Ligand Advantage
Focus
We invest in commercial and late-stage assets and leverage our technology platforms to generate royalties and revenues for our shareholders.
People
We are highly skilled investment professionals with deep scientific, clinical, and regulatory expertise.
Approach
We aggregate diverse royalty assets into a single portfolio to reduce the binary risk that comes with investing in a single drug candidate.
By the Numbers
40+
Ligand
employees
200+
portfolio
assets
4
investment
strategies
$10M-$50M
target investment
per product
All figures as of July 14, 2026, unless otherwise indicated.